Vectura, Skyepharma To Form World Respiratory Leader
This article was originally published in Scrip
Executive Summary
A UK-based global leader in respiratory therapies will be created by Vectura Group PLC's planned purchase of SkyePharma PLC in a friendly, all-stock deal to forge a combined group with estimated market capitalization of just over £1bn, joint sales of £153.9m and profits of around £50.5m.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.